BOGGIO, Elena
 Distribuzione geografica
Continente #
EU - Europa 1.339
NA - Nord America 1.020
AS - Asia 321
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 5
AF - Africa 1
Totale 2.691
Nazione #
US - Stati Uniti d'America 1.007
IE - Irlanda 414
DE - Germania 273
IT - Italia 244
SE - Svezia 200
UA - Ucraina 105
HK - Hong Kong 92
CN - Cina 90
FI - Finlandia 60
IN - India 58
SG - Singapore 46
IR - Iran 20
CA - Canada 13
FR - Francia 13
VN - Vietnam 8
CZ - Repubblica Ceca 7
GB - Regno Unito 6
GR - Grecia 6
BR - Brasile 5
EU - Europa 4
TR - Turchia 4
BE - Belgio 3
NL - Olanda 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AT - Austria 1
BD - Bangladesh 1
ES - Italia 1
KR - Corea 1
NG - Nigeria 1
Totale 2.691
Città #
Dublin 409
Jacksonville 200
Dearborn 109
Chandler 97
Hong Kong 90
Wilmington 63
Grafing 61
Piemonte 60
Lawrence 44
Princeton 44
San Mateo 31
Novara 26
Düsseldorf 25
Singapore 22
Beijing 20
Bremen 20
Helsinki 19
Turin 17
Ann Arbor 16
Milan 16
Munich 16
Monmouth Junction 14
Andover 13
Kunming 11
Ashburn 10
Mülheim 10
Hefei 9
Norwalk 9
San Giuliano Milanese 9
Toronto 9
Zanjan 9
Boardman 8
Dong Ket 8
Nanjing 8
Brno 7
Jinan 7
Ardabil 6
Cassano Magnago 6
Torino 6
Vercelli 6
Belo Horizonte 5
Berlin 5
Borgomanero 5
Bulandshahr 5
Sacramento 5
Carate 4
Kocaeli 4
Leawood 4
Nanchang 4
Ottawa 4
Redwood City 4
Strasbourg 4
Udine 4
Amsterdam 3
Asti 3
Augusta 3
Fairfield 3
Fuzhou 3
Guangzhou 3
Horia 3
Leinì 3
Menlo Park 3
Monza 3
Paris 3
Sandrigo 3
Shenyang 3
Woodbridge 3
Altavilla Monferrato 2
Brussels 2
Buffalo 2
Cambridge 2
Castelnuovo Bormida 2
Cortona 2
Legnano 2
New York 2
Odalengo Grande 2
Parma 2
Portland 2
Redmond 2
Seregno 2
Trieste 2
Aix-en-Provence 1
Assisi 1
Biella 1
Borgo Vercelli 1
Carol Stream 1
Casale Monferrato 1
Changsha 1
Chaoyang 1
Chongqing 1
Cupertino 1
Dallas 1
Dhaka 1
Falkenstein 1
Garden City 1
Genoa 1
Grafenhausen 1
Gunzenhausen 1
Göttingen 1
Hangzhou 1
Totale 1.716
Nome #
ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo 96
Differential induction of IL-17, IL-10, and IL-9 in human T helper cells by B7h and B7.1. 86
Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis 78
IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes 77
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 75
B7h Triggering Inhibits the Migration of Tumor Cell Lines 74
Immunotherapy of experimental melanoma with ICOS-Fc loaded in biocompatible and biodegradable nanoparticles 74
A mutation in caspase-9 decreases the expression of BAFFR and ICOS in patients with immunodeficiency and lymphoproliferation 72
Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis 72
Anti-cytokine autoantibodies in autoimmune diseases 71
B7H triggering inhibits osteoclast function in vitro and in vivo 69
Inducible T-Cell Costimulator Mediates Lymphocyte/Macrophage Interactions During Liver Repair 69
Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases 68
Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors 68
Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis 67
Osteopontin binds ICOSL promoting tumor metastasis 66
Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo 64
Development and characterization of solid lipid nanoparticles loaded with a highly active doxorubicin derivative 63
The -346T polymorphism of the SH2D1A gene is a risk factor for development of autoimmunity/lymphoproliferation in males with defective Fas function 63
Cerebrospinal fluid levels of tissue inhibitor of metalloproteinase 1 are increased in subjects with mild cognitive impairment 62
In Vitro and In Vivo Therapeutic Evaluation of Camptothecin-Encapsulated β-Cyclodextrin Nanosponges in Prostate Cancer 61
A double blind randomized experimental study on the use of IgM-enriched polyclonal immunoglobulins in an animal model of pneumonia developing shock 60
Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release. 58
Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome. 57
Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies 56
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity 55
Serum levels of osteopontin are increased in SIRS and sepsis 50
Triggering of B7h by the ICOS modulates maturation and migration of monocyte-derived dendritic cells. 50
Inducible t-cell costimulator ligand plays a dual role in melanoma metastasis upon binding to osteopontin or inducible t-cell costimulator 49
Improvement in the anti-tumor efficacy of doxorubicin nanosponges in in vitro and in mice bearing breast tumor models 48
Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment 48
Variations of the perforin gene in patients with multiple sclerosis 47
Genomic and functional evaluation of TNFSF14 in multiple sclerosis susceptibility 45
Platelets: 'multiple choice' effectors in the immune response and their implication in COVID-19 thromboinflammatory process 44
Mutation of FAS, XIAP, and UNC13D genes in a patient with a complex lymphoproliferative phenotype. 43
The role of osteopontin/anti-osteopontin antibodies in CIDP 41
Vitamin D Supplementation modulates ICOS+ and ICOS- regulatory T cell in siblings of Children with Type 1 Diabetes 41
The Gut-Brain-Immune Axis in Autism Spectrum Disorders: A State-of-Art Report 39
ICOSL Stimulation by ICOS-Fc Accelerates Cutaneous Wound Healing In Vivo 38
Role of tissue inhibitor of metalloproteinases-1 in the development of autoimmune lymphoproliferation 37
Paclitaxel-loaded nanosponges inhibit growth and angiogenesis in melanoma cell models 36
Immunogenetic Characterization of Primary Immune Thrombocytopenia (ITP) in Adults: Preliminary Results of the Unit Study 35
Tuning of the immune response using peptides loaded in biocompatible and biodegradable nanoparticles 34
Nanoemulsions as delivery systems for poly-chemotherapy aiming at melanoma treatment 30
Role of the C-terminal fragment of osteopontin in multiple sclerosis 30
Specific transcriptional programs differentiate ICOS from CD28 costimulatory signaling in human Naïve CD4+ T cells 29
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study 28
Cutting-Edge Delivery Systems and Adjuvants in Tolerogenic Vaccines: A Review 27
Differential Modulation of Human M1 and M2 Macrophage Activity by ICOS-Mediated ICOSL Triggering 18
Genes and Microbiota Interaction in Monogenic Autoimmune Disorders 17
ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis 16
Platelets, Protean Cells with All-Around Functions and Multifaceted Pharmacological Applications 14
Sr-Containing Mesoporous Bioactive Glasses Bio-Functionalized with Recombinant ICOS-Fc: An In Vitro Study 13
Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation 13
Electrospun Collagen Scaffold Bio-Functionalized with Recombinant ICOS-Fc: An Advanced Approach to Promote Bone Remodelling 11
Parenteral Nanoemulsions Loaded with Combined Immuno- and Chemo-Therapy for Melanoma Treatment 11
Optimization of an Injectable, Resorbable, Bioactive Cement Able to Release the Anti-Osteoclastogenic Biomolecule ICOS-Fc for the Treatment of Osteoporotic Vertebral Compression Fractures 9
Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis 3
Totale 2.775
Categoria #
all - tutte 13.745
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.745


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020437 0 4 31 2 56 74 103 15 35 72 42 3
2020/2021297 33 8 37 7 45 24 38 3 42 13 39 8
2021/2022443 44 7 28 32 19 15 82 14 29 37 42 94
2022/2023919 58 45 71 11 64 72 30 54 436 14 41 23
2023/2024392 31 26 35 11 51 12 98 13 0 7 39 69
2024/20257 7 0 0 0 0 0 0 0 0 0 0 0
Totale 2.775